Resources for you and your patients

Treatment resources

1. Getting Ready To Treat

1. GETTING READY TO TREAT WITH JYNARQUE

Complete these one-time steps to set up your practice for prescribing JYNARQUE

Icon paper tick

JYNARQUE Risk Evaluation and Mitigation Strategy (REMS) Program Enrollment (Prescriber)

Prescribers enroll and certify in the JYNARQUE REMS Program. The enrollment process takes just minutes*

GET CERTIFIED AT
JYNARQUEREMS.COM
Icon paper tick

Create Lab Account

Establish an account for your practice with either Quest or LabCorp, to facilitate compliance with REMS-required hepatic testing for your patients treated with JYNARQUE

DOWNLOAD
QUEST FORM
DOWNLOAD
LABCORP FORM
Otsuka Patient Support, Icon

JYNARQUE Prescription Process Checklist

Use this checklist as a reminder of the forms needed to prescribe patients JYNARQUE

DOWNLOAD

*Individual times may vary.

2. Preparing For Your Patient's Visit

2. PREPARING FOR YOUR PATIENT'S VISIT

JYNARQUE® (tolvaptan) Overview Brochure, Icon

REMS Patient Guide

Comprehensive guide outlining the JYNARQUE REMS Program and enrollment requirements for patients

DOWNLOAD
Icon paper tick

JYNARQUE REMS Program Patient Enrollment

Prepare the Patient Enrollment Form for your patient to sign by completing the HCP section first, either online at JYNARQUErems.com or by downloading a paper copy that can be submitted by fax

DOWNLOAD
ENROLL ONLINE
Icon paper tick

JYNARQUE REMS Program Patient Status Form

Use the form to help document hepatic monitoring for all patients treated with JYNARQUE

DOWNLOAD
Baseline Hepatic Tests, Icon

Order Baseline Hepatic Tests

Baseline liver testing is required prior to enrolling a patient in the JYNARQUE REMS program. If you created a lab account through LabCorp or Quest, you will receive the necessary test requisition forms

3. Prescribing JYNARQUE

3. PRESCRIBING JYNARQUE

JYNARQUE is exclusively available through 3 REMS-certified pharmacies:

AllianceRx Logo
Optum Logo
Panther Specialty Pharmacy Logo

The specialty pharmacies can

  • Mail medication directly to patients
  • Offer clinical and educational support by nurses and pharmacists
  • Provide lab tests and refill reminders
  • Coordinate with patients and prescribers
Prescription Referral Form, Icon

Prescription Referral Form

E-prescribe or fax a completed Prescription Referral Form to one of the REMS-certified Specialty Pharmacies

DOWNLOAD
VA Prescription Ordering Form, Icon

VA Prescription Ordering Form

The VA uses a custom prescription form due to their specific process. Fax the completed VA Prescription Form to AllianceRx

DOWNLOAD
JYNARQUE® (tolvaptan) Patient Consent Form, Icon

Otsuka Patient Support Program Consent Form (Patient)

Obtain your patient's signature on this form so that they may enroll in the Otsuka Patient Support Program. Otsuka Patient Support Service is offered by Otsuka to help patients throughout their treatment with JYNARQUE. Completed paper forms should be sent with the Prescription Referral Form to the preferred REMS-certified Specialty Pharmacy

DOWNLOAD
JYNARQUE Patient Tracker icon

JYNARQUE Patient Tracker

Keep track of the liver function monitoring tests and Patient Status Forms required by the JYNARQUE REMS Program

DOWNLOAD
INDICATION and IMPORTANT SAFETY INFORMATION

INDICATION:

JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

IMPORTANT SAFETY INFORMATION:

WARNING: RISK OF SERIOUS
LIVER INJURY

WARNING: RISK OF SERIOUS LIVER INJURY

  • JYNARQUE® (tolvaptan) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported
  • Measure transaminases (ALT, AST) and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter. Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity
  • Because of the risks of serious liver injury, JYNARQUE is available only through a Risk Evaluation and Mitigation Strategy program called the JYNARQUE REMS Program

CONTRAINDICATIONS:

  • History, signs or symptoms of significant liver impairment or injury. This contraindication does not apply to uncomplicated polycystic liver disease
  • Taking strong CYP3A inhibitors
  • With uncorrected abnormal blood sodium concentrations
  • Unable to sense or respond to thirst
  • Hypovolemia
  • Hypersensitivity (e.g., anaphylaxis, rash) to JYNARQUE or any component of the product
  • Uncorrected urinary outflow obstruction
  • Anuria

Serious Liver Injury: JYNARQUE can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported in the post-marketing ADPKD experience. Discontinuation in response to laboratory abnormalities or signs or symptoms of liver injury (such as fatigue, anorexia, nausea, right upper abdominal discomfort, vomiting, fever, rash, pruritus, icterus, dark urine or jaundice) can reduce the risk of severe hepatotoxicity. To reduce the risk of significant or irreversible liver injury, assess ALT, AST and bilirubin prior to initiating JYNARQUE, at 2 weeks and 4 weeks after initiation, then monthly for 18 months and every 3 months thereafter.

Hypernatremia, Dehydration and Hypovolemia: JYNARQUE therapy increases free water clearance which can lead to dehydration, hypovolemia and hypernatremia. Instruct patients to drink water when thirsty, and throughout the day and night if awake. Monitor for weight loss, tachycardia and hypotension because they may signal dehydration. Ensure abnormalities in sodium concentrations are corrected before initiating therapy. If serum sodium increases above normal or the patient becomes hypovolemic or dehydrated and fluid intake cannot be increased, suspend JYNARQUE until serum sodium, hydration status and volume status parameters are within the normal range.

Inhibitors of CYP3A: Concomitant use of JYNARQUE with drugs that are moderate or strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, indinavir/ritonavir, ritonavir, and conivaptan) increases tolvaptan exposure. Use with strong CYP3A inhibitors is contraindicated; dose reduction of JYNARQUE is recommended for patients taking moderate CYP3A inhibitors. Patients should avoid grapefruit juice beverages while taking JYNARQUE.

Adverse Reactions: Most common observed adverse reactions with JYNARQUE (incidence >10% and at least twice that for placebo) were thirst, polyuria, nocturia, pollakiuria and polydipsia.

Other Drug Interactions:

  • Strong CYP3A Inducers: Co-administration with strong CYP3A inducers reduces exposure to JYNARQUE. Avoid concomitant use of JYNARQUE with strong CYP3A inducers
  • V2-Receptor Agonist: Tolvaptan interferes with the V2-agonist activity of desmopressin (dDAVP). Avoid concomitant use of JYNARQUE with a V2-agonist

Pregnancy and Lactation: Based on animal data, JYNARQUE may cause fetal harm. In general, JYNARQUE should be discontinued during pregnancy. Advise women not to breastfeed during treatment with JYNARQUE.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING.

You are now leaving

JYNARQUEHCP.COM

Click "I Agree" to proceed.

I Agree

You are now leaving

JYNARQUEHCP.COM

The website you are linking to is neither owned nor controlled by Otsuka America Pharmaceutical, Inc. (Otsuka).

Otsuka is not responsible for the content or services on the site.

The reprint you are linking to may include information that is not contained in the product labeling. Please see the FULL PRESCRIBING INFORMATION, including BOXED WARNING, for complete product information.

Click "Ok" to proceed or "Cancel" to return.

OK CANCEL

Please ask your specialty pharmacy about the JYNARQUE Copay Support Program.

You are now leaving

JYNARQUEHCP.COM

Please be aware that Otsuka is not responsible for the content on the external website you are about to enter.

OK CANCEL
Cancel
INDICATION and IMPORTANT SAFETY INFORMATION
INDICATION and IMPORTANT SAFETY INFORMATION

INDICATION:

JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

IMPORTANT SAFETY INFORMATION:

WARNING: RISK OF SERIOUS
LIVER INJURY

WARNING: RISK OF SERIOUS LIVER INJURY

  • JYNARQUE® (tolvaptan) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported
  • Measure transaminases (ALT, AST) and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter. Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity
  • Because of the risks of serious liver injury, JYNARQUE is available only through a Risk Evaluation and Mitigation Strategy program called the JYNARQUE REMS Program

CONTRAINDICATIONS:

  • History, signs or symptoms of significant liver impairment or injury. This contraindication does not apply to uncomplicated polycystic liver disease
  • Taking strong CYP3A inhibitors
  • With uncorrected abnormal blood sodium concentrations
  • Unable to sense or respond to thirst
  • Hypovolemia
  • Hypersensitivity (e.g., anaphylaxis, rash) to JYNARQUE or any component of the product
  • Uncorrected urinary outflow obstruction
  • Anuria

Serious Liver Injury: JYNARQUE can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported in the post-marketing ADPKD experience. Discontinuation in response to laboratory abnormalities or signs or symptoms of liver injury (such as fatigue, anorexia, nausea, right upper abdominal discomfort, vomiting, fever, rash, pruritus, icterus, dark urine or jaundice) can reduce the risk of severe hepatotoxicity. To reduce the risk of significant or irreversible liver injury, assess ALT, AST and bilirubin prior to initiating JYNARQUE, at 2 weeks and 4 weeks after initiation, then monthly for 18 months and every 3 months thereafter.

Hypernatremia, Dehydration and Hypovolemia: JYNARQUE therapy increases free water clearance which can lead to dehydration, hypovolemia and hypernatremia. Instruct patients to drink water when thirsty, and throughout the day and night if awake. Monitor for weight loss, tachycardia and hypotension because they may signal dehydration. Ensure abnormalities in sodium concentrations are corrected before initiating therapy. If serum sodium increases above normal or the patient becomes hypovolemic or dehydrated and fluid intake cannot be increased, suspend JYNARQUE until serum sodium, hydration status and volume status parameters are within the normal range.

Inhibitors of CYP3A: Concomitant use of JYNARQUE with drugs that are moderate or strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, indinavir/ritonavir, ritonavir, and conivaptan) increases tolvaptan exposure. Use with strong CYP3A inhibitors is contraindicated; dose reduction of JYNARQUE is recommended for patients taking moderate CYP3A inhibitors. Patients should avoid grapefruit juice beverages while taking JYNARQUE.

Adverse Reactions: Most common observed adverse reactions with JYNARQUE (incidence >10% and at least twice that for placebo) were thirst, polyuria, nocturia, pollakiuria and polydipsia.

Other Drug Interactions:

  • Strong CYP3A Inducers: Co-administration with strong CYP3A inducers reduces exposure to JYNARQUE. Avoid concomitant use of JYNARQUE with strong CYP3A inducers
  • V2-Receptor Agonist: Tolvaptan interferes with the V2-agonist activity of desmopressin (dDAVP). Avoid concomitant use of JYNARQUE with a V2-agonist

Pregnancy and Lactation: Based on animal data, JYNARQUE may cause fetal harm. In general, JYNARQUE should be discontinued during pregnancy. Advise women not to breastfeed during treatment with JYNARQUE.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING.